Bleomycin 15,000unit powder for solution for injection vials
Requires a prescription from a doctor or prescriber
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0).
Genetic variations that may affect drug response
1 known genetic variation may influence how your body responds to Bleomycin 15,000unit powder for solution for injection vials.Gene involved: BLMH
These are known genetic variations. They don't mean the medicine won't work for you — speak to your doctor or a pharmacogenomics specialist for personalised advice. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bleomycin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bleomycin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Bleomycin on the MHRA register
Bleomycin 15,000unit powder for solution for injection vials
Bleomycin 15,000unit powder for solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (HTG305)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 6 · 1966–2026
Showing the 50 most relevant studies, sorted by most relevant.
Donald W. Northfelt, Bruce J. Dezube, James Thommes, et al.
Journal of Clinical Oncology, 1998
Parkash S. Gill, J Wernz, David T. Scadden, et al.
Journal of Clinical Oncology, 1996
- Acquired Immunodeficiency Syndrome
- Alopecia
- Antibiotics, Antineoplastic
Jack A. Roth, Harvey I. Pass, Margaret M. Flanagan, et al.
Journal of Thoracic and Cardiovascular Surgery, 1988
- Antineoplastic Combined Chemotherapy Protocols
- Bleomycin
- Carcinoma
A. Horwich, D.Th. Sleijfer, Sophie D. Fosså, et al.
Journal of Clinical Oncology, 1997
- Antineoplastic Combined Chemotherapy Protocols
- Bleomycin
- Cisplatin
D. Straus, C. Portlock, J. Qin, et al.
Blood, 2004
N. Srour, B. Thébaud
STEM CELLS Translational Medicine, 2015
Philipp Kolb, Chandak Upagupta, Megan Vierhout, et al.
European Respiratory Journal, 2020
- Bleomycin
- Disease Models, Animal
- Idiopathic Pulmonary Fibrosis
K. Behringer, H. Goergen, F. Hitz, et al.
Lancet, 2015
L. Bik, Tobias E. Sangers, K. Greveling, et al.
Journal of the American Academy of Dermatology, 2020
Gehr J, Hindsø L, Taudorf M, et al.
2026
- Bleomycin
- Sclerotherapy
- Vascular Malformations
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
115 minutes
Mechanism
Although the exact mechanism of action of bleomycin is unknown, available eviden…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
45%
Half-life
115 minutes
Protein binding
1%
Metabolism
Elimination
20%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1106 interactions
It may cause an allergic reaction.
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:30395541
Also involved in DNA replication and DNA recombination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01DC01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bleomycin
Additional database identifiers
Drugs Product Database (DPD)
11448
Drugs Product Database (DPD)
8453
ChemSpider
4514492
BindingDB
50122169
PDB
BLM
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6598
GenAtlas
LIG1
GeneCards
LIG1
GenBank Gene Database
M36067
GenBank Protein Database
187143
UniProt Accession
DNLI1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6600
GenAtlas
LIG3
GeneCards
LIG3
GenBank Gene Database
X84740
GenBank Protein Database
860963
UniProt Accession
DNLI3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1059
GeneCards
BLMH
UniProt Accession
BLMH_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure
ATC classifications (Wikidata)
Linked open data from Wikidata (Q415571), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons. WHO INN from the World Health Organization.